Bionano Genomics, Inc.

Good day, and welcome to the Bionano fourth quarter and full year 2023 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from Investor Relations. Please go ahead.

Thank you, and good afternoon, everyone. Welcome to the Bionano fourth quarter and full year 2023 financial results conference call. Leading the call today is Dr. Eric Holman, CEO of Bionano. He's joined by Goulson Kama, CFO of Bionano. After market closed today, Bionano issued a press release announcing its financial results for the fourth quarter and full year of 2023. A copy of the release can be found on the investor relations page of the company's website. I would like to remind everyone that certain statements made during the conference call are forward-looking, including statements about Bionano's strategic and commercialization plans, sales pipeline, future fundraising activities and prospects, cash runway, expected cost savings initiatives, and the estimated impact on annualized operating expenses, the timing of expected benefits and such initiatives, expected reductions in headcount, anticipated benefits or improvements to the Stratus, Sapphire, and ionic purification system, and their advantages over current technologies, goals, and anticipated milestones for 2024 and achievements of the Elevate Growth Strategy, our anticipated compound annual growth rate, the size of our ability to access our estimated target markets, the anticipated benefits of recent acquisitions, expectations regarding the timing and the content study results, and the anticipated benefits of these studies driving adoption of the STRATA system, SAFIRE system, and the ionic purification system. Such forward-looking statements are based on current expectations, and there can be no assurances that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks, some of which are identified in BioNano's press release and BioNano's reports filing with the SEC. These forward-looking statements are based on information available to BioNano today, and the company assumes no obligation to update statements as circumstances change. In addition, to supplement BioNano's financial results reported in accordance with the U.S. generally accepted accounting principles, or GAAP, the company is reporting non-GAAP operating expense. This non-GAAP financial measure is not meant to be considered in isolation or as a substitute to comparable GAAP measures. should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP and has no standardized meaning prescribed by GAAP and is not prepared under any comprehensive set of accounting rules or principles. A description of non-GAAP operating expense and reconciliation of non-GAAP operating expense to GAAP operating expense are included at the end of the company's earnings release issued earlier today, which has been posted on the investor relations page of the company's website. An audio recording and webcast replay for today's conference call will be available online on the investor relations page of the company's website. With that, I will turn the call over to Eric.

Thanks, David. Good afternoon, everyone, and thank you for joining us today. Today's call is an important one for BioNano. We want to cover a lot of ground, starting with an update on Q4 and the full year 2023. And then we want to cover the 2024 outlook, including important progress we are making to address our capital structure and cash burn. I would like to first turn the call over to Gulsan to cover the financial results for Q4 and full year 2023. Gulsan?